ABVC BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABVC research report →
Price Chart
About the company
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
- CEO
- Uttam Yashwant Patil
- IPO
- 2004
- Employees
- 18
- HQ
- Fremont, CA, US
Get TickerSpark's AI analysis on ABVC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $25.48M
- P/E
- -3.32
- Fwd P/E
- 0.75
- PEG
- 0.05
- P/S
- -32.01
- P/B
- 2.48
- EV/EBITDA
- -3.51
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 918.55%
- Net Margin
- 992.85%
- ROE
- -71.47%
- ROIC
- -51.98%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-7,151,259
- Net Income
- $-7,908,554-61.3%
- EPS
- $-0.39+7.1%
- OCF Growth
- -65.1%
- FCF Growth
- -65.1%
- 52W High
- $5.48
- 52W Low
- $0.71
- 50D MA
- $0.98
- 200D MA
- $1.36
- Beta
- 0.51
- RSI (14)
- 45
- Avg Volume
- 111.36K
No earnings-call transcripts are available for ABVC yet.
- Free Float
- 78.6%
- Shares Outstanding
- 26.00M
- Float Shares
- 20.44M
of shares held by institutions
9 13F filers
Held by 20 ETFs
Biggest fund positions in ABVC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 22 | Jiang Shuling | other | 0 |
| Aug 2, 21 | An Chihliang | other | 0 |
| Aug 2, 21 | Sakamoto Norimi | other | 0 |
| Aug 2, 21 | Odaira Yoshinobu | other | 0 |
| Aug 2, 21 | Jiang Tsung Shann | other | 0 |
| Aug 2, 21 | Miao Shin-Yu | other | 0 |
| Nov 8, 21 | Tseng Shih-Chen | other | 0 |
| Aug 2, 21 | Jiang Eugene | other | 0 |
| Aug 2, 21 | Jiang Chang-Jen | other | 0 |
| Aug 2, 21 | King Chi-Hsin Richard | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABVC coverage
Recent articles, reports, and earnings notes.
No research on ABVC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABVC report →Critical Survey: ABVC BioPharma (NASDAQ:ABVC) vs. Takeda Pharmaceutical (NYSE:TAK)
defenseworld.net · Sep 9
Contrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)
defenseworld.net · Apr 27
ABVC BioPharma (NASDAQ:ABVC) Stock Price Down 3.4% – Time to Sell?
defenseworld.net · Apr 24
ABVC BioPharma (NASDAQ:ABVC) Trading Up 11.3% – Here’s Why
defenseworld.net · Apr 2
ABVC BioPharma (NASDAQ:ABVC) Trading Down 4.9% – Here’s What Happened
defenseworld.net · Dec 30
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
globenewswire.com · Dec 11
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
globenewswire.com · Oct 22
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
globenewswire.com · Aug 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.